Publicacións nas que colabora con Sonia Eiras Penas (62)

2024

  1. Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers

    Journal of Translational Medicine, Vol. 22, Núm. 1

  2. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry

    American Journal of Medicine, Vol. 137, Núm. 8, pp. 761-769.e1

  3. Endocrine activity of dysfunctional adipose tissue: Cardiovascular risk and progression markers

    International Journal of Cardiology

  4. Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients with Coexistent Heart Failure and Atrial Fibrillation

    Journal of Cardiovascular Translational Research, Vol. 17, Núm. 1, pp. 13-23

  5. FABP4 Enhances Lipidic and Fibrotic Cardiac Structural and Ca2+ Dynamic Changes

    Circulation: Arrhythmia and Electrophysiology, Vol. 17, Núm. 9, pp. e012683

  6. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network

    Cardiovascular Diabetology, Vol. 23, Núm. 1

  7. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry

    Revista Espanola de Cardiologia

2023

  1. Clinical Profiling and Biomarkers for Post-Operative Atrial Fibrillation Prediction in Patients Undergoing Cardiac Surgery

    Journal of Clinical Medicine, Vol. 12, Núm. 10

  2. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  3. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

2022

  1. Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators

    International journal of molecular sciences, Vol. 23, Núm. 14

  2. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1

  3. Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue-molecules and SGLT2i dapagliflozin

    Journal of Cellular and Molecular Medicine, Vol. 26, Núm. 16, pp. 4416-4427

  4. The Effect of Mineralocorticoid Receptor 3 Antagonists on Anti-Inflammatory and Anti-Fatty Acid Transport Profile in Patients with Heart Failure

    Cells, Vol. 11, Núm. 8

  5. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

2021

  1. A New Biomarker Tool for Risk Stratification in “de novo” Acute Heart Failure (OROME)

    Frontiers in Physiology, Vol. 12

  2. Higher ACE2 expression levels in epicardial cells than subcutaneous stromal cells from patients with cardiovascular disease: Diabetes and obesity as possible enhancer

    European Journal of Clinical Investigation, Vol. 51, Núm. 5

  3. Sex-related differences of fatty acid-binding protein 4 and leptin levels in atrial fibrillation

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 23, Núm. 5, pp. 682-690

  4. Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value

    Journal of Molecular Medicine, Vol. 99, Núm. 12, pp. 1741-1753

  5. Updates on epicardial adipose tissue mechanisms on atrial fibrillation

    Obesity Reviews, Vol. 22, Núm. 9